- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about SRRK
Recent news which mentions SRRK
Why Scholar Rock Shares Are Trading Higher Today
June 17, 2022
From Benzinga
From Benzinga
U.S. Markets Open Higher; Dow Rises Around 200 Points
June 17, 2022
From Benzinga
79 Biggest Movers From Yesterday
June 08, 2022
From Benzinga
From Benzinga
Stocks That Hit 52-Week Lows On Friday
May 27, 2022
From Benzinga
81 Biggest Movers From Yesterday
May 18, 2022
From Benzinga
From Benzinga
48 Stocks Moving In Tuesday's Mid-Day Session
May 17, 2022
From Benzinga
From Benzinga
Stocks That Hit 52-Week Lows On Tuesday
April 26, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Thursday
April 21, 2022
From Benzinga
From Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
April 03, 2022
From Benzinga
From Benzinga
Stocks That Hit 52-Week Lows On Wednesday
March 16, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Monday
March 14, 2022
From Benzinga
Scholar Rock To Highlight Apitegromab Data From Ambulatory Cohort In Muscular Dystrophy
March 14, 2022
Tickers
SRRK
From Benzinga
Stocks That Hit 52-Week Lows On Friday
January 14, 2022
From Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
December 22, 2021
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2021
December 22, 2021
From Benzinga
Scholar Rock Outlines Pivotal Apitegromab Trial Design In Spinal Muscular Atrophy Patients
December 01, 2021
Tickers
SRRK
From Benzinga
48 Stocks Moving In Friday's Mid-Day Session
November 26, 2021
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
November 19, 2021
From Benzinga
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
September 29, 2021
From Benzinga
48 Biggest Movers From Yesterday
September 21, 2021
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.